Literature DB >> 15761282

Elderly patients with head and neck cancer: the influence of comorbidity on choice of therapy, complication rate, and survival.

Wynia Derks1, Rob J de Leeuw, Gerrit Jan Hordijk.   

Abstract

PURPOSE OF REVIEW: Comorbidity may be an important reason for head and neck surgeons to treat elderly patients less intensively. This article provides an overview of the influence of age and comorbidity on choice of therapy, postoperative complications, and survival. RECENT
FINDINGS: Several retrospective studies show that elderly patients can undergo surgery if they do not have severe comorbid disorders. Severe comorbidity influences the rate of postoperative complications, and the higher complication rate in older patients reported in some studies is probably due to a higher level of comorbidity. Comorbidity also affects the survival of cancer patients, but several studies have failed to detect a relation between age and survival after correction for comorbidity. Thus, although severe comorbidity may influence the choice of treatment, patient age as such should not be a reason to exclude patients from intensive therapy.
SUMMARY: If severe comorbidity is not present, elderly patients should receive standard treatment for head and neck cancer. Treatment choice should be based on medical findings and patient preference, not on chronologic age.

Entities:  

Mesh:

Year:  2005        PMID: 15761282     DOI: 10.1097/01.moo.0000156169.63204.39

Source DB:  PubMed          Journal:  Curr Opin Otolaryngol Head Neck Surg        ISSN: 1068-9508            Impact factor:   2.064


  19 in total

Review 1.  Comorbidity in patients with cancer of the head and neck: prevalence and impact on treatment and prognosis.

Authors:  Jay F Piccirillo; Anna Vlahiotis
Journal:  Curr Oncol Rep       Date:  2006-03       Impact factor: 5.075

2.  Advances in the care of head and neck cancer patients at Baylor University Medical Center.

Authors:  John C O'Brien
Journal:  Proc (Bayl Univ Med Cent)       Date:  2008-01

Review 3.  Management of head and neck cancer in elderly patients.

Authors:  Yassine Lalami; Gilberto de Castro; Chantal Bernard-Marty; Ahmad Awada
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

4.  Significance of age and comorbidity as prognostic indicators for patients with bladder cancer.

Authors:  Moon Soo Ha; In Ho Chang
Journal:  Asian J Androl       Date:  2010-08-02       Impact factor: 3.285

5.  On the need for comprehensive assessment of impact of comorbidity in elderly patients with head and neck cancer.

Authors:  Afshin Teymoortash; Gyorgy B Halmos; Carl E Silver; Primož Strojan; Missak Haigentz; Alessandra Rinaldo; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-07-25       Impact factor: 2.503

6.  Oncological and surgical outcome of total laryngectomy in combination with neck dissection in the elderly.

Authors:  Afshin Teymoortash; Franziska Bohne; Lena Kissing; Hanna Daniel; Bilgen Kurt; Thomas Wilhelm; Gyorgy B Halmos; Stephan Hoch
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-03-14       Impact factor: 2.503

7.  Prognostic impact of comorbidity in patients with bladder cancer.

Authors:  Ifeanyichukwu I Megwalu; Anna Vlahiotis; Mohamed Radwan; Jay F Piccirillo; Adam S Kibel
Journal:  Eur Urol       Date:  2007-11-05       Impact factor: 20.096

Review 8.  Treatment in elderly patients with head and neck cancer : A challenging dilemma.

Authors:  A Teymoortash; A Ferlito; G B Halmos
Journal:  HNO       Date:  2016-04       Impact factor: 1.284

9.  Does age influence disease-specific survival in patients with squamous cell carcinomas of the head and neck?

Authors:  Joan Lop; Cristina Valero; Jacinto García; Miquel Quer; Ian Ganly; Jatin P Shah; Snehal G Patel; Xavier León
Journal:  J Surg Oncol       Date:  2020-03-09       Impact factor: 3.454

10.  Comorbidity, human papillomavirus infection and head and neck cancer survival in an ethnically diverse population.

Authors:  Ashish A Ankola; Richard V Smith; Robert D Burk; Michael B Prystowsky; Catherine Sarta; Nicolas F Schlecht
Journal:  Oral Oncol       Date:  2013-07-25       Impact factor: 5.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.